 Ryan Fischer
Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 13 | 2023 | 38 | 4.340 |
Why?
| | Liver Diseases | 5 | 2023 | 14 | 1.690 |
Why?
| | Humans | 37 | 2023 | 6257 | 1.250 |
Why?
| | Immunosuppressive Agents | 6 | 2019 | 36 | 1.220 |
Why?
| | Sirolimus | 6 | 2019 | 8 | 1.160 |
Why?
| | Male | 25 | 2022 | 3210 | 1.120 |
Why?
| | Postoperative Complications | 4 | 2020 | 181 | 1.100 |
Why?
| | Fontan Procedure | 2 | 2021 | 14 | 1.000 |
Why?
| | Dendritic Cells | 4 | 2011 | 6 | 0.960 |
Why?
| | Child | 22 | 2023 | 3020 | 0.930 |
Why?
| | Female | 21 | 2022 | 3322 | 0.910 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 9 | 0.810 |
Why?
| | Patient Compliance | 2 | 2020 | 71 | 0.800 |
Why?
| | Cryptosporidiosis | 1 | 2020 | 3 | 0.800 |
Why?
| | Immunocompromised Host | 1 | 2020 | 9 | 0.800 |
Why?
| | Esophageal Neoplasms | 1 | 2020 | 1 | 0.780 |
Why?
| | Head and Neck Neoplasms | 1 | 2020 | 1 | 0.780 |
Why?
| | Scalp | 1 | 2020 | 2 | 0.780 |
Why?
| | Adenocarcinoma | 1 | 2020 | 5 | 0.780 |
Why?
| | Skin Neoplasms | 1 | 2020 | 8 | 0.770 |
Why?
| | Neoplasms | 1 | 2021 | 102 | 0.760 |
Why?
| | Anemia, Hemolytic, Congenital | 1 | 2019 | 3 | 0.730 |
Why?
| | Hydrops Fetalis | 1 | 2019 | 4 | 0.720 |
Why?
| | Electronic Health Records | 1 | 2019 | 59 | 0.710 |
Why?
| | Child, Preschool | 13 | 2022 | 1474 | 0.690 |
Why?
| | Infant | 14 | 2023 | 1392 | 0.680 |
Why?
| | Adolescent | 15 | 2022 | 2029 | 0.680 |
Why?
| | Graft Rejection | 3 | 2020 | 31 | 0.660 |
Why?
| | Immune Tolerance | 3 | 2021 | 8 | 0.630 |
Why?
| | Intestines | 2 | 2013 | 26 | 0.610 |
Why?
| | Retrospective Studies | 13 | 2023 | 1232 | 0.600 |
Why?
| | Animals | 6 | 2021 | 853 | 0.540 |
Why?
| | Intestinal Atresia | 1 | 2013 | 11 | 0.500 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2013 | 9 | 0.500 |
Why?
| | Treatment Outcome | 10 | 2021 | 622 | 0.480 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2022 | 15 | 0.480 |
Why?
| | Hypertension, Portal | 2 | 2022 | 7 | 0.450 |
Why?
| | Cholangitis, Sclerosing | 2 | 2023 | 2 | 0.450 |
Why?
| | Isoantigens | 2 | 2011 | 2 | 0.440 |
Why?
| | Myeloid Cells | 1 | 2011 | 1 | 0.420 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2011 | 10 | 0.420 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2022 | 22 | 0.420 |
Why?
| | Bone Marrow Transplantation | 1 | 2011 | 18 | 0.420 |
Why?
| | Hepatolenticular Degeneration | 1 | 2011 | 2 | 0.420 |
Why?
| | Heart Defects, Congenital | 2 | 2023 | 74 | 0.410 |
Why?
| | Cholestasis, Intrahepatic | 2 | 2021 | 3 | 0.400 |
Why?
| | Fatty Liver | 2 | 2013 | 4 | 0.390 |
Why?
| | Short Bowel Syndrome | 3 | 2015 | 4 | 0.390 |
Why?
| | Patient Participation | 2 | 2020 | 21 | 0.370 |
Why?
| | Muscular Dystrophy, Duchenne | 2 | 2019 | 2 | 0.360 |
Why?
| | Liver Failure | 2 | 2019 | 2 | 0.290 |
Why?
| | Liver Cirrhosis | 3 | 2023 | 9 | 0.290 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2020 | 4 | 0.280 |
Why?
| | Forkhead Transcription Factors | 2 | 2020 | 5 | 0.280 |
Why?
| | Transition to Adult Care | 2 | 2022 | 16 | 0.270 |
Why?
| | Vancomycin | 2 | 2023 | 18 | 0.270 |
Why?
| | Young Adult | 6 | 2022 | 610 | 0.260 |
Why?
| | Middle Aged | 3 | 2021 | 555 | 0.250 |
Why?
| | Vascular Diseases | 1 | 2023 | 8 | 0.240 |
Why?
| | Insurance | 1 | 2023 | 1 | 0.240 |
Why?
| | Intestine, Small | 2 | 2013 | 15 | 0.240 |
Why?
| | Cholestasis | 1 | 2022 | 1 | 0.230 |
Why?
| | Alagille Syndrome | 1 | 2022 | 1 | 0.230 |
Why?
| | Diagnosis, Differential | 2 | 2020 | 79 | 0.230 |
Why?
| | Digestive System Diseases | 1 | 2022 | 1 | 0.230 |
Why?
| | Adult | 6 | 2022 | 1128 | 0.230 |
Why?
| | Gastroenterology | 1 | 2022 | 17 | 0.220 |
Why?
| | Tumor Microenvironment | 1 | 2021 | 7 | 0.220 |
Why?
| | Heart Transplantation | 2 | 2020 | 12 | 0.220 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 11 | 0.220 |
Why?
| | Cohort Studies | 2 | 2020 | 256 | 0.220 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2022 | 20 | 0.220 |
Why?
| | Adenosine Triphosphatases | 1 | 2021 | 3 | 0.210 |
Why?
| | Bile Acids and Salts | 1 | 2021 | 2 | 0.210 |
Why?
| | T-Lymphocytes | 2 | 2013 | 36 | 0.210 |
Why?
| | Tacrolimus | 2 | 2019 | 9 | 0.210 |
Why?
| | Biliary Tract Diseases | 1 | 2020 | 4 | 0.200 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 245 | 0.200 |
Why?
| | Diarrhea | 1 | 2020 | 18 | 0.200 |
Why?
| | Weight Reduction Programs | 1 | 2020 | 24 | 0.200 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 2020 | 2 | 0.190 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 15 | 0.190 |
Why?
| | Liver Function Tests | 1 | 2019 | 3 | 0.190 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 11 | 0.190 |
Why?
| | Antipsychotic Agents | 1 | 2019 | 10 | 0.190 |
Why?
| | Anticonvulsants | 1 | 2019 | 25 | 0.190 |
Why?
| | United States | 2 | 2019 | 630 | 0.190 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2011 | 11 | 0.190 |
Why?
| | Graft Survival | 1 | 2019 | 31 | 0.190 |
Why?
| | Incidence | 1 | 2019 | 129 | 0.180 |
Why?
| | Genetic Therapy | 1 | 2019 | 5 | 0.180 |
Why?
| | Ion Channels | 1 | 2019 | 4 | 0.180 |
Why?
| | Ascites | 1 | 2019 | 4 | 0.180 |
Why?
| | Hepatoblastoma | 1 | 2019 | 7 | 0.180 |
Why?
| | Liver Neoplasms | 1 | 2019 | 13 | 0.180 |
Why?
| | Transplantation Tolerance | 2 | 2010 | 2 | 0.180 |
Why?
| | Drainage | 1 | 2019 | 37 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 124 | 0.170 |
Why?
| | Thrombelastography | 1 | 2018 | 2 | 0.170 |
Why?
| | Infant, Premature | 1 | 2019 | 84 | 0.170 |
Why?
| | Resuscitation | 1 | 2018 | 6 | 0.170 |
Why?
| | Blood Transfusion | 1 | 2018 | 14 | 0.170 |
Why?
| | Pediatric Obesity | 1 | 2020 | 120 | 0.170 |
Why?
| | Necrobiotic Xanthogranuloma | 1 | 2018 | 1 | 0.170 |
Why?
| | Dissection | 1 | 2018 | 3 | 0.170 |
Why?
| | Cicatrix | 1 | 2018 | 5 | 0.170 |
Why?
| | Caregivers | 1 | 2018 | 37 | 0.170 |
Why?
| | Skin | 1 | 2018 | 15 | 0.170 |
Why?
| | Pregnancy | 1 | 2019 | 255 | 0.170 |
Why?
| | Glucocorticoids | 1 | 2018 | 31 | 0.160 |
Why?
| | Liver | 2 | 2022 | 133 | 0.160 |
Why?
| | Quality of Life | 1 | 2018 | 125 | 0.160 |
Why?
| | Intestinal Diseases | 2 | 2013 | 4 | 0.150 |
Why?
| | Prognosis | 2 | 2021 | 176 | 0.150 |
Why?
| | Bilirubin | 3 | 2023 | 22 | 0.150 |
Why?
| | Health Resources | 1 | 2015 | 17 | 0.140 |
Why?
| | Prospective Studies | 3 | 2022 | 490 | 0.140 |
Why?
| | Pneumonia, Aspiration | 1 | 2015 | 9 | 0.140 |
Why?
| | Mice | 3 | 2011 | 433 | 0.130 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 106 | 0.130 |
Why?
| | Severity of Illness Index | 2 | 2013 | 141 | 0.130 |
Why?
| | Stem Cell Transplantation | 1 | 2013 | 10 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 22 | 0.130 |
Why?
| | Graft vs Host Disease | 1 | 2013 | 12 | 0.130 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 29 | 0.130 |
Why?
| | Parenteral Nutrition, Total | 1 | 2013 | 7 | 0.120 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2013 | 1 | 0.120 |
Why?
| | Calcineurin | 1 | 2013 | 2 | 0.120 |
Why?
| | Pancreas Transplantation | 1 | 2013 | 2 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2013 | 5 | 0.120 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2013 | 1 | 0.120 |
Why?
| | Fish Oils | 1 | 2013 | 1 | 0.120 |
Why?
| | Infant, Newborn | 3 | 2023 | 811 | 0.110 |
Why?
| | Apoptosis | 1 | 2012 | 61 | 0.110 |
Why?
| | Portal Vein | 2 | 2023 | 8 | 0.110 |
Why?
| | Lymphocyte Activation | 2 | 2009 | 10 | 0.110 |
Why?
| | Transplantation, Isogeneic | 1 | 2011 | 1 | 0.110 |
Why?
| | Cell Survival | 1 | 2011 | 18 | 0.110 |
Why?
| | Mice, Knockout | 1 | 2011 | 89 | 0.100 |
Why?
| | Body Mass Index | 2 | 2022 | 144 | 0.100 |
Why?
| | Risk Assessment | 2 | 2021 | 129 | 0.100 |
Why?
| | Biopsy | 3 | 2018 | 55 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2021 | 303 | 0.100 |
Why?
| | Metformin | 1 | 2009 | 3 | 0.090 |
Why?
| | Antigen Presentation | 1 | 2009 | 1 | 0.090 |
Why?
| | Chemotaxis | 1 | 2009 | 3 | 0.090 |
Why?
| | Immunotherapy, Adoptive | 1 | 2009 | 6 | 0.090 |
Why?
| | B-Lymphocytes | 1 | 2009 | 19 | 0.090 |
Why?
| | Cytokines | 1 | 2009 | 48 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 61 | 0.090 |
Why?
| | Patient Education as Topic | 1 | 2009 | 64 | 0.090 |
Why?
| | Recurrence | 2 | 2019 | 115 | 0.080 |
Why?
| | Signal Transduction | 1 | 2009 | 146 | 0.080 |
Why?
| | Obesity | 1 | 2009 | 127 | 0.080 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 1 | 0.080 |
Why?
| | Pediatrics | 2 | 2019 | 173 | 0.080 |
Why?
| | Allografts | 2 | 2019 | 6 | 0.080 |
Why?
| | Steroids | 2 | 2019 | 12 | 0.080 |
Why?
| | Disease Progression | 2 | 2019 | 96 | 0.070 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 3 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 16 | 0.060 |
Why?
| | Parenteral Nutrition | 1 | 2023 | 7 | 0.060 |
Why?
| | Registries | 1 | 2023 | 80 | 0.060 |
Why?
| | Prevalence | 1 | 2023 | 141 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2022 | 18 | 0.060 |
Why?
| | Immunity, Humoral | 1 | 2022 | 14 | 0.060 |
Why?
| | Alanine Transaminase | 1 | 2022 | 4 | 0.060 |
Why?
| | Aspartate Aminotransferases | 1 | 2022 | 4 | 0.060 |
Why?
| | Patient Transfer | 1 | 2022 | 7 | 0.060 |
Why?
| | Vaccination | 1 | 2022 | 63 | 0.060 |
Why?
| | Antibodies, Viral | 1 | 2022 | 45 | 0.060 |
Why?
| | Societies, Medical | 1 | 2022 | 45 | 0.060 |
Why?
| | Secondary Prevention | 1 | 2022 | 7 | 0.060 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2022 | 15 | 0.050 |
Why?
| | Urban Population | 1 | 2022 | 36 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2021 | 1 | 0.050 |
Why?
| | Codon, Nonsense | 1 | 2021 | 6 | 0.050 |
Why?
| | Rural Population | 1 | 2022 | 36 | 0.050 |
Why?
| | Survival Analysis | 1 | 2021 | 38 | 0.050 |
Why?
| | Data Mining | 1 | 2021 | 5 | 0.050 |
Why?
| | Data Collection | 1 | 2021 | 31 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2021 | 113 | 0.050 |
Why?
| | Ikaros Transcription Factor | 1 | 2020 | 2 | 0.050 |
Why?
| | Databases, Factual | 1 | 2021 | 102 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2020 | 17 | 0.050 |
Why?
| | Age Factors | 1 | 2021 | 213 | 0.050 |
Why?
| | Aged | 1 | 2021 | 297 | 0.050 |
Why?
| | Waiting Lists | 1 | 2019 | 12 | 0.050 |
Why?
| | Risk | 1 | 2019 | 23 | 0.050 |
Why?
| | Tissue and Organ Procurement | 1 | 2019 | 16 | 0.050 |
Why?
| | Algorithms | 1 | 2020 | 94 | 0.050 |
Why?
| | Patient Preference | 1 | 2019 | 6 | 0.050 |
Why?
| | Risk Factors | 1 | 2021 | 394 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2019 | 32 | 0.050 |
Why?
| | Cisplatin | 1 | 2019 | 6 | 0.050 |
Why?
| | Patient Safety | 1 | 2019 | 19 | 0.040 |
Why?
| | Quality Improvement | 1 | 2019 | 59 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 44 | 0.040 |
Why?
| | Kidney Diseases | 1 | 2019 | 71 | 0.040 |
Why?
| | Kidney | 1 | 2019 | 90 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 106 | 0.040 |
Why?
| | Plasma | 1 | 2018 | 6 | 0.040 |
Why?
| | Back | 1 | 2018 | 1 | 0.040 |
Why?
| | Thigh | 1 | 2018 | 5 | 0.040 |
Why?
| | Abdomen | 1 | 2018 | 14 | 0.040 |
Why?
| | Parents | 1 | 2019 | 141 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2015 | 21 | 0.040 |
Why?
| | Hospital Costs | 1 | 2015 | 27 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 59 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2015 | 130 | 0.030 |
Why?
| | Critical Illness | 1 | 2015 | 21 | 0.030 |
Why?
| | Inpatients | 1 | 2015 | 44 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 33 | 0.030 |
Why?
| | Length of Stay | 1 | 2015 | 234 | 0.030 |
Why?
| | Hospitalization | 1 | 2015 | 183 | 0.030 |
Why?
| | Transaminases | 1 | 2013 | 1 | 0.030 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 1 | 0.030 |
Why?
| | Plasmapheresis | 1 | 2013 | 2 | 0.030 |
Why?
| | Hemolysis | 1 | 2013 | 3 | 0.030 |
Why?
| | Transplantation | 1 | 2013 | 2 | 0.030 |
Why?
| | Everolimus | 1 | 2013 | 2 | 0.030 |
Why?
| | Rituximab | 1 | 2013 | 3 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 2013 | 7 | 0.030 |
Why?
| | Cyclosporine | 1 | 2013 | 6 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2013 | 9 | 0.030 |
Why?
| | Penicillins | 1 | 2013 | 7 | 0.030 |
Why?
| | Medical Records | 1 | 2013 | 14 | 0.030 |
Why?
| | Body Height | 1 | 2013 | 34 | 0.030 |
Why?
| | Nebraska | 1 | 2013 | 2 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2013 | 10 | 0.030 |
Why?
| | Hyperbilirubinemia | 1 | 2013 | 9 | 0.030 |
Why?
| | Nephrotic Syndrome | 1 | 2013 | 24 | 0.030 |
Why?
| | Triglycerides | 1 | 2013 | 21 | 0.030 |
Why?
| | Intestinal Volvulus | 1 | 2013 | 15 | 0.030 |
Why?
| | Gastroschisis | 1 | 2013 | 28 | 0.030 |
Why?
| | Epithelium | 1 | 2012 | 7 | 0.030 |
Why?
| | Observer Variation | 1 | 2012 | 12 | 0.030 |
Why?
| | Time Factors | 1 | 2013 | 258 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2012 | 180 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2010 | 28 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2010 | 111 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2007 | 7 | 0.020 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2007 | 6 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2007 | 10 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 17 | 0.020 |
Why?
| | Up-Regulation | 1 | 2007 | 27 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2007 | 106 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|